Delivery Order SPE2DB24D3013-SPE2DB25FFNUG
- Not listed
- The U.S. Defense Department's Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $1,385.52 for ORGOVYX 120 mg tablets (30-unit package) on July 22, 2025, with an ultimate completion date of August 12, 2025. This firm fixed-price, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with the Defense Logistics Agency Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December...
- The Defense Logistics Agency's Medical Supply Chain has awarded a delivery order valued at $5,542.08 to AmerisourceBergen Drug Corp for the supply of ORGOVYX 120 mg tablets in quantities of 30 units. This competitive award, issued on July 24, 2025, with an ultimate completion date of August 14, 2025, utilizes firm fixed price pricing with no set-aside designation. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $8,313.12 on July 29, 2025, for the supply of ORGOVYX 120 mg tablets in quantities of 30 units. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is scheduled for completion by August 19, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of ORGOVYX 120 mg tablets in quantities of 30 units, with a ceiling value of $1,385.52 and a firm fixed price contract type. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The award carries no set-aside designation,...
- The Defense Logistics Agency awarded a delivery order valued at $1,385.52 to AmerisourceBergen Drug Corp for 30 units of ORGOVYX 120 mg tablets under a firm fixed-price contract with an ultimate completion date of August 19, 2025. This non-set-aside award was issued on July 29, 2025, and represents a direct procurement through the federal medical supply chain. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for military and...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,385.52 to AmerisourceBergen Drug Corp for ORGOVYX 120 mg tablets (30-count unit of use packaging) with a firm fixed price structure. The order was competitively awarded without set-aside designation and is scheduled for completion by August 11, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this delivery from its corporate office location in the same city. This delivery order is...
- The Defense Logistics Agency has awarded a delivery order valued at $2,771.04 to AmerisourceBergen Drug Corp for the supply of ORGOVYX 120 mg tablets in quantities of 30. The contract, designated as non-competitive with a firm fixed price structure, is scheduled for completion by August 21, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location. This delivery order operates as a...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for ORGOVYX 120 mg tablets in quantities of 30, with a contract ceiling value of $8,313.12 and an ultimate completion date of August 18, 2025. This is a firm fixed-price, non-set-aside delivery order for pharmaceutical supplies to support federal medical procurement needs. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical...
- The Defense Logistics Agency awarded a delivery order valued at $1,385.52 to AmerisourceBergen Drug Corp for ORGOVYX 120 mg tablets (30-count unit of use packaging) with a firm fixed price and an ultimate completion date of August 11, 2025. This non-set-aside, competitively awarded delivery order represents a pharmaceutical supply transaction to support federal medical procurement needs. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical...
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, for the supply of ORGOVYX 120 MG TABLET in 30-count vials. The $3,989.67 contract has an ultimate completion date of April 17, 2024. AmerisourceBergen Drug Corp, through its Corporate Office division in Conshohocken, Pennsylvania, is the prime contractor. This delivery order contract is part of a larger...
- SPE2DB24D3013Indefinite Delivery Contract
- SPE2DB24D3013-SPE2DB25FFNUGDelivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,385.52 for ORGOVYX 120 mg tablets (30-count units) with a firm fixed price structure. This contract is unset-aside and was competitively awarded on July 28, 2025, with an ultimate completion date of August 18, 2025. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a transaction under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026, which serves as a comprehensive pharmaceutical supply vehicle for military healthcare systems globally. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that functions as a critical vendor for federal medical procurement, particularly supporting Defense Health Agency and military healthcare programs. The company's pharmaceutical supply portfolio under its DLA prime contract encompasses specialty medications, brand-name and generic drugs, vaccines, and medical supplies across multiple therapeutic domains. ORGOVYX is a specialty pharmaceutical product used in prostate cancer treatment, reflecting the company's capability to deliver specialized oncology medications alongside its broader medical supply services to support military and veteran healthcare requirements worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.4k | 7/28/25 |